Aloxi palonosetron regulatory update

FDA approved oral Aloxi palonosetron 0.5 mg to prevent chemotherapy-induced nausea and vomiting (CINV) associated with initial and repeat courses of moderately emetogenic chemotherapy. Eisai, which ha...